SCHEMBL6096038

SCHEMBL6096038

COc1ccc(C(=O)c2c(N)sc3c2CCSC3)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
MAPT P10636 6/20 0.56
KDM4E B2RXH2 3/20 0.56
GAA P10253 3/20 0.56
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TDP1 Q9NUW8 2/20 0.49
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HTT P42858 1/20 0.44
FLT3 P36888 1/20 0.44
ADORA1 P30542 1/20 0.43
MCL1 Q07820 1/20 0.43
TLR9 Q9NR96 1/20 0.43
GLO1 Q04760 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5676779 0.84 ALDH1A1 (0.68) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL134640 0.83 MEN1 (0.67) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL4060800 0.83 TDP1 (0.71) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL14195744 0.78 MAPT (0.65) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3913429 0.74 ALDH1A1 (0.62) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3498187 0.74 ALDH1A1 (0.62) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL4140103 0.72 MAPT (0.67) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3499288 0.72 MAPT (1.00) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL5118588 0.72 MEN1 (0.53) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL3777713 0.71 TDP1 (0.69) MEN1KMT2AMAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067527-B2 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
EP-1259515-B1 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA PHARMACEUTICAL (JP) 2004-11-10 EP disclosed
US-20040054183-A1 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
US-6653476-B2 Antiinflammatory and antiarthritic agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-11-25 US disclosed
US-20030130517-A1 Thienopyridine derivatives , their production and use TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130517-A1 Thienopyridine derivatives , their production and use ALK, HRH2, TBXA2R MEN1 4809/4885KMT2A 866/4885MAPT 3749/4885
US-20040054183-A1 Thienopyridine derivatives, their production and use ALK, HRH2, TBXA2R MEN1 4809/4885KMT2A 866/4885MAPT 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.